This newsletter presents you the following key sessions:
1. Podcast with dr. Jordi Remón-Masip about the safety and efficacy of osimertinib versus sequential gefitinib
and osimertinib in patients with EGFR-mutant NSCLC
2. Podcast with Prof. Niels Reinmuth about the patterns of response in metastatic NSCLC after 2 and 4 cycles
of chemotherapy, alone or with durvalumab ± tremelimumab
3. Podcast with Prof. Saadettin Kiliçkap about cemiplimab monotherapy as first-line treatment of patients with
brain metastases from advanced NSCLC